|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4985 | (2006.01) |
| C07D 471/14 | (2013.01) | ||
| C07D 471/14 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| C07B 59/002 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/4985 | (2013.01) | ||
| C07D 471/16 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| C07D 471/16 | (2013.01) | ||
| C07B 59/00 | (2006.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 1/00 | (2006.01) | ||
| A61P 21/02 | (2018.01) | ||
| A61P 3/04 | (2006.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 21/02 | (2006.01) | ||
| A61P 25/04 | (2018.01) | ||
| A61P 25/14 | (2018.01) | ||
| A61P 25/04 | (2006.01) | ||
| A61P 25/16 | (2018.01) | ||
| A61P 25/14 | (2006.01) | ||
| A61P 25/18 | (2018.01) | ||
| A61P 25/16 | (2006.01) | ||
| A61P 25/18 | (2006.01) | ||
| A61P 25/20 | (2018.01) | ||
| A61P 25/20 | (2006.01) | ||
| A61P 25/22 | (2018.01) | ||
| A61P 25/22 | (2006.01) | ||
| A61P 25/24 | (2018.01) | ||
| A61P 25/24 | (2006.01) | ||
| A61P 25/28 | (2018.01) | ||
| A61P 29/02 | (2006.01) | ||
| A61P 29/02 | (2018.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 3/04 | (2018.01) | ||
| A61P 25/28 | (2006.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Number of the document | 3125893 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15773589.5 |
| Date of filing the European patent application | 2015-04-03 | |
| (97) | Date of publication of the European application | 2017-02-08 |
| (45) | Date of publication and mention of the grant of the patent | 2023-09-20 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/024340 |
| Date | 2015-04-03 |
| (87) | Number | WO 2015/154025 |
| Date | 2015-10-08 |
| (30) | Number | Date | Country code |
| 201461975610 P | 2014-04-04 | US |
| (72) |
MATES, Sharon , US
LI, Peng , US
WENNOGLE, Lawrence P. , US
DAVIS, Robert , US
|
| (73) |
Intra-Cellular Therapies, Inc. ,
430 East 29th Street, Suite 900, New York, NY 10016,
US
|
| (54) | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS |
| DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS |